offline
Biogen up 1% on Q1 beat and strong Spinraza sales
Biogen (NASDAQ:BIIB) Q1 results: Revenues: $3,489.8M (+11.5%); Product Sales: $2,680M (+6.2%); Anti-CD20 Revenues: $517.4M (+16.7%); Other: $292.4M (+77.9%).
Net Income: $1,408.8M (+20.1%); EPS: $7.15 (+29.1%); Non-GAAP Net Income: $1,374.4M (+7.2%); Non-GAAP EPS: $6.98 (+15.4%); CF Ops: $1.5B.
...
https://seekingalpha.com/news/3453349-bi...raza-sales
![[Bild: BIIBc1dl0908.png]](https://finviz.com/publish/042519/BIIBc1dl0908.png)
Biogen (NASDAQ:BIIB) Q1 results: Revenues: $3,489.8M (+11.5%); Product Sales: $2,680M (+6.2%); Anti-CD20 Revenues: $517.4M (+16.7%); Other: $292.4M (+77.9%).
Net Income: $1,408.8M (+20.1%); EPS: $7.15 (+29.1%); Non-GAAP Net Income: $1,374.4M (+7.2%); Non-GAAP EPS: $6.98 (+15.4%); CF Ops: $1.5B.
...
https://seekingalpha.com/news/3453349-bi...raza-sales
__________________
